Sun Pharma misses Q1 estimates as US generics sales fall 9.7%
Sun Pharma’s Q1 revenue rose 10.5% to ₹15,299 crore and net profit increased 27%, led by 16% India sales growth. US sales fell 9.7% amid generic-drug pricing pressure and competition, while innovative medicines grew 12.8%. Its Organon acquisition is targeted to close in Q4 FY27.
Sun Pharma missed Q1 Street estimates despite 16% growth in its India business. US generics sales fell 9.7% amid pricing pressure and competition, while innovative medicines grew. Its $11.75 billion Organon acquisition has shareholder approval and is targeted to close in Q4 FY27.
Why this matters
The result follows Sun Pharma’s reported 27% Q1 profit gain on 16% India formulations growth, Brazil semaglutide approval, and its planned $11.8B Organon acquisition.
Retail-company signals are accelerating, up 259640% QoQ.